Tag | Content |
---|---|
UniProt Accession | E2AK2_HUMAN; P19525; |
Entrez ID | 5610 |
GenBank Protein ID | NM_001135651.2; NM_001135652.2; NM_002759.3; XM_011532987.2; |
GenBank Nucleotide ID | NP_001129123.1; NP_001129124.1; NP_002750.1; XP_011531289.1; |
Protein Name | Interferon-induced, double-stranded RNA-activated protein kinase (EC 2.7.11.1) (Eukaryotic translation initiation factor 2-alpha kinase 2) (eIF-2A protein kinase 2) (Interferon-inducible RNA-dependent protein kinase) (P1/eIF-2A protein kinase) (Protein ki |
Gene Name | EIF2AK2; PKR; PRKR |
Organism | Homo sapiens |
NCBI Taxa ID | 9606 |
Functional Description | IFN-induced dsRNA-dependent serine/threonine-protein kinase which plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1). Inhibits viral replication via phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1), this pho(view all) |
Sequence (Fasta) | MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK 60 KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ 120 CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG 180 SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK 240 RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY 300 NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK 360 CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI 420 FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE 480 LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK 540 KSPEKNERHT C 552 |
|
Database | Annotation |
---|---|
CTD (Curated) (count: 3) | MESH:D007251
; Influenza, Human MESH:D013226 ; Status Epilepticus MESH:D011471 ; Prostatic Neoplasms |
GWASdb (count: 4) | rs4233920; Lung function (forced expiratory volume in 1 second to forced vital capacity ratio); lung disease
rs4648195; Type 2 diabetes; type 2 diabetes mellitus rs4648196; Type 2 diabetes; type 2 diabetes mellitus rs2254958; Cardiovascular disease; cardiovascular system disease |
PTM | Modification Sites |
---|---|
Phosphorylation (count: 28) (view all) | 101 EGLSMGNYIGLINRI dbPAF
142 CKMGQKEYSIGTGST dbPAF 162 QLAAKLAYLQILSEE dbPAF 179 VKSDYLSSGSFATTC dbPAF 181 SDYLSSGSFATTCES dbPAF 242 NQRKAKRSLAPRFDL dbPAF |
Acetylation (count: 7) (view all) | 134 GPEGFHYKCKMGQKE PLMD
140 YKCKMGQKEYSIGTG PLMD 304 RVKYNNEKAEREVKA PLMD 416 KLIHRDLKPSNIFLV PLMD 426 NIFLVDTKQVKIGDF PLMD 509 IISDIFDKKEKTLLQ PLMD |
Ubiquitination (count: 17) (view all) | 159 EAKQLAAKLAYLQIL PLMD
253 RFDLPDMKETKYTVD PLMD 26 QKQGVVLKYQELPNS PLMD 268 KRFGMDFKEIELIGS PLMD 291 AKHRIDGKTYVIKRV PLMD 299 TYVIKRVKYNNEKAE PLMD |
Methylation (count: 2) | 61 EGEGRSKKEAKNAAA PLMD
69 EAKNAAAKLAVEILN PLMD |
Network | Interaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|